Oncology & Cancer

Sorafenib modestly increases progression-free survival

Sorafenib, a tyrosine kinase inhibitor (TKI) targeting the receptors for vascular endothelial growth factor, platelet derived growth factor, and mast/stem cell growth factor, modestly increases progression-free survival (PFS), ...

Oncology & Cancer

Novel mechanism that protects from glioblastoma identified

A group of researchers at the Spanish National Cancer Research Centre (CNIO) have identified a protein called RanBP6 as a new regulator of EGFR. In a paper published in Nature Communications they show how silencing of RanBP6 ...

Oncology & Cancer

Validation of an IHC screening tool for ROS1 gene rearrangements

Immunohistochemistry (IHC) is an effective tool that can be used for identifying proto-oncogene 1 receptor tyrosine kinase (ROS1) gene rearrangements and screening patients for the administration of the targeted therapy crizotinib, ...

Oncology & Cancer

Chemo-free treatment a possibility for leukemia / lymphoma

Patients with terminal forms of leukaemia and lymphoma who have run out of treatment options could soon benefit from a new drug, which not only puts an end to chemotherapy and has virtually no side effects but also improves ...

Oncology & Cancer

Researchers find two new methods to determine ALK status

The implementation of personalized health care in cancer relies on the identification and characterization of cancer biomarkers and the availability of accurate detection systems and therapies for those biomarkers. Anaplastic ...

page 22 from 26